4-[(R,S)-2-methylsulfinylphenyl]piperidine | 161609-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(R,S)-2-methylsulfinylphenyl]piperidine
• 英文别名: 4-[(S)-2-methylsulfinylphenyl]-piperidine；4-(2-methylsulfinylphenyl)piperidine；4-(2-(S)-Methyl-sulfinylphenyl)piperidine
• CAS: 161609-95-6
• 化学式: C₁₂H₁₇NOS
• 分子量: 223.339
• InChiKey: GETHXZBPJVUSBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(R,S)-2-methylsulfinylphenyl]piperidine 在 溴 、 三乙胺 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 反应 19.33h， 生成 4-[4-bromo-2-methylsulfinylphenyl]-N-Cbz-piperidine
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  N-phenylmethoxycarbonyl-4-(2-methylsulfinylphenyl)piperidine 在 甲苯 、 final residue 、 dichloromethane MeOH Et3N 作用下， 以 三氟乙酸 为溶剂， 反应 0.75h， 以afforded the named product (0.87 g)的产率得到4-[(R,S)-2-methylsulfinylphenyl]piperidine
  参考文献：
  名称：

  Aryl substituted heterocycles

  摘要：

  本发明涉及公式I所示的芳基取代杂环的新用途，该杂环对内源性神经肽Tachykinins之一及神经肽2（NK2）受体的药理作用具有拮抗作用，因此在需要拮抗作用的情况下，如哮喘和相关疾病的治疗中，它们非常有用。本发明还提供了含有芳基取代杂环的制药组合物，用于上述治疗。本发明还提供了公式I的某些新的芳基取代杂环和其制造的新中间体。 ##STR1##

  公开号：

  US05654299A1

文献信息

• Cyclic amide derivatives for treating asthma
  申请人：Zeneca Limited

  公开号：US05589489A1

  公开（公告）日：1996-12-31

  Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式I的化合物##STR1##其中Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4具有规范中给定的任意含义，它们的N-氧化物以及它们的药用盐是神经激肽A的非肽拮抗剂，可用于治疗哮喘等。还公开了制药组合物、制备式I化合物和中间体的方法。
• N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
  申请人：Astrazeneca AB

  公开号：US06403601B1

  公开（公告）日：2002-06-11

  Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

  式（I）的化合物，其中R2是一个可以被取代的5,6,7,8-四氢萘基团（在此定义的其余基团），以及含有这些化合物的药物组合物和使用这些化合物治疗NK1和/或NK2受体拮抗有益的方法。
• N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
  申请人：Astra Zeneca AB

  公开号：US06365602B1

  公开（公告）日：2002-04-02

  A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.

  公式I的化合物中：R是烷基；R1是可选择地取代的苯基2-氧代四氢-1(2H)-嘧啶基，或2-氧代-1-哌啶基；R2是氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺基、酰基、烷基、氨基甲酰基、N-烷基氨基甲酰基、N,N-二烷基氨基甲酰基（其中烷基基团相同或不同）、羟基、硫代酰基、硫代氨基甲酰基、N-烷基硫代氨基甲酰基、或N,N-二烷基硫代氨基甲酰基（其中烷基基团相同或不同）。X1和X2独立地为氢或卤素，但至少X1或X2中的一个为卤素；R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基、或烷基磺酰基，它们是至少一种催吐肽受体的拮抗剂，对治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病情况有用。描述了它们的制备方法，以及含有它们和它们的用途的组合物。
• Substituted oximes as neurokinin antagonists
  申请人：Schering Corporation

  公开号：US06063926A1

  公开（公告）日：2000-05-16

  Compounds within the genus represented by the structural formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; ##STR2## R.sup.4 is methyl or ethyl; and Z is substituted piperidinyl.

  该属内的化合物由结构式I表示，或其药学上可接受的盐，其中：T是取代苯基或取代吡啶基; R4是甲基或乙基; Z是取代哌啶基。
• Neurokinin antagonists for use as medicaments
  申请人：——

  公开号：US20030158170A1

  公开（公告）日：2003-08-21

  A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

  一种具有通式(I)的化合物，以及使用此类化合物治疗疾病的方法和包含此类化合物的制药组合物。